Phathom Pharmaceuticals (PHAT) EBIAT (2022 - 2025)
Historic EBIAT for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$30.0 million.
- Phathom Pharmaceuticals' EBIAT rose 6497.54% to -$30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$274.6 million, marking a year-over-year increase of 1911.8%. This contributed to the annual value of -$334.3 million for FY2024, which is 6584.29% down from last year.
- Latest data reveals that Phathom Pharmaceuticals reported EBIAT of -$30.0 million as of Q3 2025, which was up 6497.54% from -$75.8 million recorded in Q2 2025.
- In the past 5 years, Phathom Pharmaceuticals' EBIAT registered a high of -$30.0 million during Q3 2025, and its lowest value of -$94.3 million during Q1 2025.
- Over the past 4 years, Phathom Pharmaceuticals' median EBIAT value was -$55.0 million (recorded in 2022), while the average stood at -$62.2 million.
- In the last 5 years, Phathom Pharmaceuticals' EBIAT crashed by 12322.96% in 2024 and then soared by 6497.54% in 2025.
- Quarter analysis of 4 years shows Phathom Pharmaceuticals' EBIAT stood at -$55.0 million in 2022, then crashed by 44.55% to -$79.6 million in 2023, then rose by 6.43% to -$74.5 million in 2024, then surged by 59.74% to -$30.0 million in 2025.
- Its last three reported values are -$30.0 million in Q3 2025, -$75.8 million for Q2 2025, and -$94.3 million during Q1 2025.